Phase 1: Initial Partnerships with Major Police Departments
DermaVision will establish strategic partnerships with several large, influential police departments in California to validate our technology and gather real-world feedback. These initial partnerships will serve as proof points for our solution's effectiveness and help refine our product and services.
Phase 2: Post-Market Surveillance and Expansion
Building on the success of our initial partnerships, we will conduct post-market surveillance to gather data on DermaVision's performance and impact in the field. This data will support our expansion efforts as we actively market to and onboard remaining police departments and other government agencies across the United States.
Phase 3: Broader Adoption and New Markets
With a strong foothold in the law enforcement market, we will explore opportunities to expand into adjacent markets, such as healthcare and social services, where our technology can significantly impact injury detection and documentation across all skin tones.
Supporting Initiatives
FDA Approval: We are pursuing FDA approval via the de novo pathway to classify DermaVision as a Class I medical device, further validating its safety and efficacy.
Networking and Events: We actively participate in networking events, trade shows, and public events to showcase our technology and engage with potential customers and partners.
Trial Periods: We offer discounted trial periods to new users, allowing them to experience the benefits of DermaVision firsthand and build confidence in our solution.
